Nnejm.org: September 27, 2012
The Diabetes Prevention Program (DPP) clinical trial and its 10-year outcomes study (DPPOS), both sponsored by the National Institutes of Health (NIH), showed that certain interventions could prevent or substantially delay the onset of type 2 diabetes both safely and cost-effectively.1,2 Yet diabetes prevention is not widely practiced in the United States, and the disease’s staggering human and financial costs continue to grow. It is therefore essential to identify the factors impeding the full realization of the DPP interventions’ potential for preventing diabetes.
The DPP was a comparative effectiveness trial involving 3234 overweight or obese adults with impaired glucose tolerance (prediabetes). Forty-five percent of the participants belonged to racial or ethnic minority groups that have an increased risk of type 2 diabetes. Participants were assigned to receive one of three interventions: lifestyle intervention aimed at modest weight loss through diet and exercise, treatment with generic metformin, or a placebo control. Read More